Qiagen (NYSE:QGEN) Upgraded at Wolfe Research

Wolfe Research upgraded shares of Qiagen (NYSE:QGEN) from a peer perform rating to an outperform rating in a research report report published on Thursday morning, Marketbeat reports. They currently have $50.00 target price on the stock.

Other equities research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. boosted their target price on Qiagen from $52.00 to $54.00 and gave the company an overweight rating in a research note on Tuesday, June 18th. Stifel Nicolaus dropped their price objective on Qiagen from $55.00 to $45.00 and set a hold rating on the stock in a research note on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Qiagen has a consensus rating of Moderate Buy and a consensus target price of $51.05.

Qiagen Trading Down 0.0 %

NYSE QGEN opened at $41.09 on Thursday. The stock has a market capitalization of $9.38 billion, a price-to-earnings ratio of 27.55, a PEG ratio of 3.18 and a beta of 0.42. The stock’s 50 day moving average price is $43.23 and its two-hundred day moving average price is $43.57. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.45 and a current ratio of 1.84. Qiagen has a 52 week low of $34.74 and a 52 week high of $47.70.

Qiagen (NYSE:QGEN) last released its earnings results on Monday, April 29th. The company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.44 by $0.02. The firm had revenue of $459.00 million for the quarter, compared to analysts’ expectations of $453.91 million. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The business’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.53 EPS. As a group, analysts anticipate that Qiagen will post 2.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in QGEN. Norges Bank acquired a new position in shares of Qiagen during the 4th quarter worth approximately $264,322,000. Nuance Investments LLC increased its holdings in shares of Qiagen by 311.0% during the 1st quarter. Nuance Investments LLC now owns 4,493,489 shares of the company’s stock worth $193,175,000 after acquiring an additional 3,400,255 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Qiagen by 81.0% during the 3rd quarter. Wellington Management Group LLP now owns 6,054,116 shares of the company’s stock worth $245,299,000 after acquiring an additional 2,709,030 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Qiagen by 8.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 24,066,569 shares of the company’s stock valued at $1,045,211,000 after buying an additional 1,809,486 shares in the last quarter. Finally, Earnest Partners LLC grew its holdings in Qiagen by 85.1% in the 1st quarter. Earnest Partners LLC now owns 3,427,605 shares of the company’s stock valued at $147,353,000 after buying an additional 1,576,259 shares in the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.